anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In clinical trials, treatment with albendazole has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. There have also been case reports of acute liver failure of uncertain causality and hepatitis [see Adverse Reactions (6)]. 

Monitor liver enzymes (transaminases) before the start of each treatment cycle and at least every 2 weeks during treatment. If hepatic enzymes exceed twice the upper limit of normal, consideration should be given to discontinuing albendazole therapy based on individual patient circumstances. Restarting albendazole treatment in patients whose hepatic enzymes have normalized off treatment is an individual decision that should take into account the risk/benefit of further albendazole tablets usage. Perform laboratory tests frequently if albendazole treatment is restarted.

Patients with elevated liver enzyme test results are at increased risk for hepatotoxicity and bone marrow suppression [see Warnings and Precautions (5.1)]. Discontinue therapy if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.
A method may include receiving data about a first person and a second person, the first person having a contagion. The method may include determining whether a first location is within a proximity distance to a second location. The method may include determining whether a first time is within a proximity time period with a second time. The method may include defining a proximity relationship for the second person relative to the first person. The defined proximity relationship may be positive when the first location is within the proximity distance and first time is within the proximity time period, or the defined proximity relationship may be negative when either the first location is not within the proximity distance or first time is not within the proximity time period. When the proximity relationship is positive, the second person may be labeled as being contaminated by the contagion.
Objective: To investigate the relationship between the polymorphism of endoplasmic reticulum aminopeptidase 1 (ERAP-1) gene and the occurrence of pre-eclampsia (PE). Methods: A case-control study was conducted in Beijing Obstetrics and Gynecology Hospital from October 2018 to October 2021. A total of 51 PE pregnant women with onset gestational age<34 weeks were selected as the PE group, and 48 normal pregnant women during the same period were selected as the control group. Venous blood samples were collected from the pregnant women before delivery and umbilical cord within 5 minutes after delivery. Single nucleotide polymorphisms (SNP) of ERAP-1 gene in the pregnant women and their fetus were detected by next-generation sequencing. Univariate analysis and multivariate logistic regression analysis were used to analyze all the SNP loci and alleles detected in the two groups, and the significant SNP were screened. Results: (1) A total of 13 target SNP loci of maternal ERAP-1 gene were selected by univariate analysis. Among them, the frequency distribution of genotypes at 96096828, 96121524, 96121715, 96122260 and 96122281 showed statistically significant differences between PE group and control group (all P<0.05). Multivariate logistic regression analysis showed that the risk of PE in pregnant women with TC genotype at locus 96121524 was 2.002 times higher than those with TT genotype (95%CI: 0.687-5.831, P=0.020). (2) A total of 4 target SNP loci of ERAP-1 gene in fetal were selected by univariate analysis, and there was no statistical significance in gene polymorphism of the 4 loci between PE group and control group (all P>0.05). Multivariate logistic regression analysis showed that the risk of PE in fetus with genotype AA at locus 96121406 was 0.236 times that of fetus with genotype GG (95%CI: 0.055-1.025, P=0.016). Conclusion: ERAP-1 gene with TC genotype at 96121524 in the mother and GG genotype at 96121406 in the fetus might be related to the incidence of PE.
An infusion pump system including an infusion pump device and a RFID reader. The infusion pump device comprises at least a controller, a communication interface, and a fluidic pump. The RFID reader includes at least a microcontroller, a memory storage, an RFID manager, and an RFID reader communication device. The RFID manager is configured to read a user identification parameter from a RFID device. The RFID reader communication device of the RFID reader is configured to communicate with an access unit connected to a network, to query user-related information based on the user identification from a server over the network. The RFID reader communication device is configured to communicate with the communication interface of the infusion pump to forward the user related information to the infusion pump device
FIELD: biotechnology, medicine. SUBSTANCE: Lingud broth is purified by ultrafiltration on diaphragms at retention limit value 20 kDa, not less. Then the obtained permeate is subjected for heat or cold sterilization by microfiltration on diaphragms at pore diameter 0.45 nm, not above (if medium will be used immediately) or 0.22 nm, not above (for medium storage). Sowing material of diphtheric corynebacteria strain is added to the purified broth and cultivation is carried out under aeration and stirring under toxin formation control followed by toxin separation from the cultural fluid. After ultrafiltration heterogeneity of nutrient medium is decreased, high-molecular inhibitors of toxin formation were removed. Change of heat sterilization for microfiltration allows to retain growth factors and vitamins in medium that are destructed partially at heat sterilization. Method provides the preparing diphtheric toxins with high titers. EFFECT: improved method and quality of toxin, nutrient medium preparing. 3 ex
The invention discloses a cynanchum chinense extract and a preparation method thereof. The preparation method comprises the following steps: (1) selecting overground part stem leaves of calamus plant medicine, extracting with water or an ethanol-water mixed solvent, and concentrating and filtering an extracting solution; and (2) absorbing the extracting solution with macroporous resin or polyamide, carrying out gradient elution with the ethanol-water mixed solvent, collecting eluted parts of corresponding target products, and concentrating and drying the eluted parts to obtain the cynanchum chinense extract. The cynanchum chinense extract comprises more than 30mg/g of Tricin-7-O-Beta-D-glucuronide, and at least two components of tricin, kaempferol-3-O-Beta-D- glucopyranoside, apigenin and kaempferol. Plant resources of the preparation method disclosed by the invention can be recycled. The preparation method disclosed by the invention has the advantages of economic and reasonable process route, high efficiency, low energy consumption, convenience in recovering and recycling the solvent, and easiness in realizing the industrial production. The cynanchum chinense extract has the anti-inflammatory action, and can be applied in anti-inflammatory medicine.
Surgical excision of hyper-pigmented gingival tissue using conventional surgical blade (#15) under local anaesthesia. Application of periodontal dressing followed by post-operative instructions.
Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
PROBLEM TO BE SOLVED: To obtain a hair tonic, composed of a specific plant extract and having excellent falling-off preventing effect and growth stimulating effect on hair. SOLUTION: This hair tonic contains an extract of Cabe Jawa, belonging to Piperaceae and used as a folk medicine or a crude medicine in Indonesia, as an active component. The compounding amount of the extract is 0.005-20wt.% based on the whole amount of the hair tonic in terms of a dry matter. The extract is prepared by extracting Cabe Jawa, as it is or after drying if necessary and in the shape as it is or crushed, with a solvent such as ethanol. The extract is formulated to a tonic, a hair cream, a mousse, a shampoo, a rinse, etc., by adequately compounding the extract with a known additive. The hair tonic has falling-off preventing effect and hair growth stimulating effect superior to a pepper on a mammal including a human.
The invention relates to a compound fructus evodiae composition. The compound fructus evodiae composition comprises, by weight, 5-20 parts of fructus evodiae, 0.5-2 parts of semen strychni and 0.5-2 parts of radix glycyrrhizae. The invention further provides a compound fructus evodiae gel containing the compound fructus evodiae composition and a preparation method of the compound fructus evodiae gel. The compound fructus evodiae composition and the compound fructus evodiae gel can be used for relieving pain caused by cancers. Under the synergistic action of a reasonable ratio of the fructus evodiae, the semen strychni and the radix glycyrrhizae, the compound fructus evodiae composition is excellent in cancer pain resistance effect, low in toxicity and safe to use. The compound fructus evodiae gel is excellent in transdermal absorption performance and good in stability and can be stored for a long term.
Disclosed are personal care compositions, especially hair styling compositions, comprising from about 0.01 % to about 20 % of a non-silicone containing polymer suitable for hair styling; an amount of organopolysiloxane microemulsion such that the personal care composition comprises from about 0.01 % to about 10 % of organopolysiloxane; from about 0.1 % to about 20 % of a liquid hydrophilic non-polymeric cationic compound containing at least one quaternary ammonium moiety; and from about 3 % to about 99 % of a carrier. The organopolysiloxane microemulsion is substantially free of amino groups in combination with hydroxyl groups, has an average particle size of less than about 80 nanometers, and comprises a surfactant system for dispersing the organopolysiloxane in the microemulsion. The carrier in turn comprises from about 3 % to about 99 %, by weight of the composition, of a first solvent selected from the group consisting of water; water soluble organic solvents;  organic solvents having strong to moderately strong hydrogen-bonding parameters; and mixtures thereof (excluding compounds disclosed as second solvents); and optionally, from about 0 % to about 55 % of a second solvent selected from the group consisting of C1-C3 monohydric alcohols, C1-C3 ketones, C1-C3 ethers, and mixtures thereof. The personal care composition in the present invention provides good style retention and improved hair aesthetics, e.g. blacker, shinier hair, without the disadvantages of stiff or sticky compositions. In addition, the present invention provides these same attributes while containing lower alcohols. Furthermore, it has been found that incorporation of select styling polymers and plasticizers provides additionally a restyle benefit.
The group uses videos and texts processed with the blue channel 1D defocus and 30% blue light filtering for visual evoked tasks. Participants will engage in a 50-minute visual evoked task using videos and texts that have been processed with the 1D blue channel and partially filtered for blue light. The impact of the standard video mode on the eye's axial length, refractive labor, and visual function is evaluated, including but not limited to indicators such as reading efficiency, blinking detection, and retinal fundus blood flow.
Techniques presented herein disclose a method for generating a derived observation for a care plan assigned to a patient. According to one embodiment, an application executing on a care platform server receives an event log having a plurality of events. Each event includes one or more types of biometric data for the patient. The care plan includes one or more definitions for metrics that are derived from the one or more types of biometric data. A temporal slice of the event log is selected based on one or more of the definitions. The derived metrics are generated by evaluating events within the selected temporal slice of the event log against one or more of the definitions. A condition of the patient is evaluated based on the derived metrics.
There was minimum potential for systemic exposure to VYJUVEK. Antibodies against the viral vector (HSV-1) and transgene protein (COL7) were evaluated in a subset of subjects in the randomized, intra-subject placebo-‑controlled clinical study. A total of 64% of evaluated subjects (14/22) were anti-HSV-1 antibody positive at baseline. Six of the 8 anti-HSV-1 seronegative subjects seroconverted by Week 26 following treatment with VYJUVEK. For subjects with available matched baseline and end-of-study serum samples, anti‑drug antibodies (ADAs) to COL7 were detected in 72% (13/18) of subjects treated with VYJUVEK for up to 26 weeks. Data are limited to perform correlative assessment on the impact of ADA on pharmacodynamic activity.
Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
The present invention relates to an aromatase inhibitor. Aromatase is key enzyme which catalyzes androgen in an animal body to be converted into estrogen. The level of estrogen in the body can be reduced by inhibiting the activity of the aromatase, so the proportion of the androgen to the estrogen in the animal body is enhanced, and an animal is induced to grow towards the male direction. The present invention discovers that letrozole can be used as the aromatase inhibitor. In the process of inducing the sex reversal of rockfishes in advance, the operation is simple and convenient, the effect is obvious, and the economic value is high. In addition, the letrozole is not a sex hormone, and the letrozole can not cause the hormone pollution to the environment.
OBJECTIVES: Spermatic cord sarcomas are exceedingly rare, often misdiagnosed and subsequently improperly treated at local hospitals. This retrospective study looked at the oncological outcomes of spermatic cord sarcoma cases managed with curative intent resection at a tertiary referral sarcoma centre. We specifically studied how initial inadequate resections impact the oncologic outcomes compared to primary tumour resections at the reference centre.
METHODS: One hundred eighteen consecutive patients affected by primary, localized spermatic cord sarcoma surgically managed at our reference centre from January 2001 through January 2021 were included. Primary endpoints were local relapse free (LRFS), distant metastasis free (DMFS) and overall survival (OS). These outcomes were evaluated with multi-nomial logistic regression and Cox proportional hazards regression models for a co-relation to known patient, tumour and treatment-related prognostic factors, including a prior inadequate resection and time from diagnosis to a complete oncologic resection as independent variables. Secondarily, we compared the above variables and treatment intervals among the subgroups of primary versus re-resection surgery.
RESULTS: Over a median follow-up of 54 months (IQR 25-105), 12 patients (10.2%) developed local recurrence (LR) and 14 (11.6%) had distant metastasis (DM). 5-year local relapse (LRFS) and distant metastasis-free survival (DMFS) were 89.3% and 86.5%, respectively. Higher tumour grade and size were associated with a worse DMFS (p=<0.05). Likewise, marginal (R1) resection correlated with an inferior LRFS (p=< 0.05). Eighty-four patients (71.2%) had their initial diagnosis established on an inadequate surgical excision performed in a local hospital, followed by a re-excision at our centre (Re-resection group). During the same period, 34 (28.8%) were managed primarily with biopsy and treatment at our reference centre (Primary-resection group). The two groups had statistically significant differences in tumour size, histopathology, surgery duration, rate of postoperative complication and R0 resection (p < 0.005). Additionally, the difference in time intervals to achieve the treatment targets was statistically insignificant and did not correlate to the risk of recurrence as an independent variable. Residual disease was present in 51.2 % (n = 43) of the re-excision specimens. However, following a complete R0 resection, this did not correlate with a higher risk of recurrence (p = 0.481).
CONCLUSION: Prompt referral to a tertiary centre, where multidisciplinary evaluation and sound oncologic resections are the standard of treatment, can align the OS and DFS of patients receiving incomplete surgery elsewhere to those treated primarily in referral centres. The primary determinant of prognosis remains surgical margin, tumour size and grade.
APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
The role of a specific E2 region,  869 CKWGGNWTCV 878 , containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. A recombinant CSFV (FPi.c) containing mutations in three amino acid residues within the E2 protein area comprised CSFV amino acid residues 869-878 was constructed: W871T, W875D, and V878T. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 10 5  TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination. Protection was evidenced by absence of clinical signs related with CSF as well as the absence of viremia produced by the challenge virulent virus.
The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
In controlled studies in adult patients, a higher proportion of patients treated with LYRICA reported blurred vision (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing. Less than 1% of patients discontinued LYRICA treatment due to vision-related events (primarily blurred vision).

Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuity was reduced in 7% of patients treated with LYRICA, and 5% of placebo-treated patients. Visual field changes were detected in 13% of LYRICA-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of LYRICA-treated and 2% of placebo-treated patients.

Although the clinical significance of the ophthalmologic findings is unknown, inform patients to notify their physician if changes in vision occur. If visual disturbance persists, consider further assessment. Consider more frequent assessment for patients who are already routinely monitored for ocular conditions [see Patient Counseling Information (17)].
Stabilized plain or effervescent tablets are prepd. from solids residues of medicinal or refreshment herbal teas. Dried powders are obtd. by various methods of drying, namely on vacuum-drums, by spraying etc. The powders are formed into granules by moistening them with alcohol and redrying. Ethanol and/or isopropanol is then added in sufficient concns. to form a complex solid structure. Alcohol and aqueous microcrystalline hydrate clusters are formed in this multicomponent system, which facilitate compression and improve the stability of tablets.
Risk Summary

There is no information about the presence of atorvastatin in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. However, it has been shown that another drug in this class passes into human milk. Studies in rats have shown that atorvastatin and/or its metabolites are present in the breast milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk (see Data). Statins, including atorvastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. 

Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with atorvastatin calcium tablets [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1)].  


Data   


Following a single oral administration of 10 mg/kg of radioactive atorvastatin to lactating rats, the concentration of total radioactivity was determined. Atorvastatin and/or its metabolites were measured in the breast milk and pup plasma at a 2:1 ratio (milk:plasma).
PROBLEM TO BE SOLVED: To produce the subject composition excellent in suppressing effects on an unpleasant taste felt in a mouth and capable of more readily carrying out the flavoring by removing water from a granulated material prepared by granulating an ingredient having the unpleasant taste with a specific aqueous dispersion. SOLUTION: This composition is produced by removing water from a granulated material prepared by granulating (A) an ingredient having an unpleasant taste with (B) an aqueous dispersion of a sparingly water-soluble polymer (e.g. ethyl cellulose). A medicine such as a physiologically active ingredient, a food additive, etc., are cited as the ingredient A. Fursultiamine, ranitidine hydrochloride, vitamins, minerals, etc., are cited as the physiologically active ingredient. Thiamine nitrate, riboflavin, ascorbic acid, etc., are cited as the food additive. The average particle diameter of the ingredient A is preferably 1-100 μm, more preferably 1-50 μm, far more preferably 1-30 μm, especially preferably 1-20 μm. The concentration of the ingredient B is preferably 5-40 wt.% expressed in terms of the solid content.
Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.